WEI ZHU: Open Payments
NPI 1104234863 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$998 in 23 payments from 12 companies in 2025. Trend: 2023 $811 · 2024 $1,093 · 2025 $998
Food & beverage: $998
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 3 | $203 |
| Incyte Corporation | 3 | $183 |
| Syndax Pharmaceuticals, Inc. | 4 | $131 |
| Adaptive Biotechnologies Corporation | 1 | $118 |
| SOBI, INC | 3 | $98 |
| Merck Sharp & Dohme LLC | 2 | $62 |
| Celgene Corporation | 2 | $55 |
| AstraZeneca Pharmaceuticals LP | 1 | $33 |
| Rigel Pharmaceuticals, Inc. | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
Products named: JAKAFI, Xospata, clonoSEQ, REBLOZYL, Vonjo, CALQUENCE, TAVALISSE, Gamifant.
Industry payments across TX — which companies pay providers there.
